Key result
Peripheral revascularization shows similar 7-day bleeding rates to coronary revascularization and amputation.
Why the study?
The relationship between invasive vascular procedures and bleeding in patients with peripheral artery disease has not been well described.
What is the incidence, timing, and severity of periprocedural bleeding following invasive vascular procedures in patients with peripheral artery disease?
RCT (n=2,661)
randomized
Yes
What is the incidence, timing, and severity of periprocedural bleeding following invasive vascular procedures in patients with peripheral artery disease?
In patients with peripheral artery disease, the incidence and severity of major or minor bleeding within 7 days of peripheral revascularization are comparable to those following coronary revascularization or lower extremity amputation.
Answers are grounded in this paper and cite their sources.
Similar bleeding rates after peripheral vs coronary revascularization warrant equivalent periprocedural vigilance; extends limited PAD-specific evidence.
BACKGROUND: The relationship between invasive vascular procedures and bleeding in patients with peripheral artery disease has not been well described in the literature. This post hoc analysis from the EUCLID trial (Examining Use of Ticagrelor in Peripheral Artery Disease) aimed to describe the incidence of major and minor postprocedural bleeding and characterize the timing and severity of bleeding events relative to the procedure. METHODS: EUCLID was a multicenter, randomized controlled trial of 13 885 patients with symptomatic peripheral artery disease that tested the efficacy and safety of ticagrelor compared with clopidogrel for the prevention of major adverse cardiovascular events. A total of 2661 patients underwent 3062 coronary revascularization, peripheral revascularization, and amputation during the study. The primary safety end point was Thrombolysis in Myocardial Infarction major or minor bleeding. All bleeding events were formally adjudicated by a clinical end point classification group. RESULTS: Major bleeding events most often occurred ≤7 days following the procedure. The incidence of Thrombolysis in Myocardial Infarction major or minor bleeding ≤7 days following peripheral revascularization (3.3%; 95% CI, 2.5%-4.1%) was similar to rates after coronary revascularization (4.0%; 95% CI, 2.6%-5.4%) and lower extremity amputation (2.3%; 95% CI, 0.8%-3.8%). The severity of bleeding events (as graded by drop in hemoglobin, need for transfusion, bleeding in a critical location, and fatal bleeding) was also similar following peripheral, coronary revascularization, and lower extremity amputation. CONCLUSIONS: The incidence of Thrombolysis in Myocardial Infarction major/minor bleeding following peripheral revascularization is comparable to rates after coronary revascularization and lower extremity amputation, and the majority of bleeding events occur within 7 days following the procedure. The severity of periprocedural bleeding is also similar after procedures, with the most frequently adjudicated reason being a drop in hemoglobin ≥2 g/dL. Future studies should be performed to enhance our understanding of bleeding risk related to revascularization and amputation procedures in peripheral artery disease patients.
No takes yet. Share an insight, caveat, or question.
Kansal et al. (2019) conducted an RCT in symptomatic peripheral artery disease (n=2,661). Peripheral revascularization vs. Coronary revascularization and lower extremity amputation was evaluated on Thrombolysis in Myocardial Infarction major or minor bleeding ≤7 days following the procedure. Peripheral revascularization was associated with a similar incidence of major or minor bleeding within 7 days compared to coronary revascularization and lower extremity amputation.
Synapse has enriched 10 related papers. Consider them for comparative context: